Four Insiders Sell Shares at Lab Instrument Firm 10x Genomics
10x Genomics, Inc.
Four insiders at 10x Genomics, a maker of laboratory analytical instruments, have sold shares in the last month. The company's revenue has grown, but it has not yet turned a profit, though losses narrowed in 2025 and operating cash flow has become positive.
- 4 company insiders sold within 30 days
What turned up
Four insiders at 10x Genomics, Inc. sold company stock within the last 30 days, according to public filings. The company makes instruments and software used in biological research.
What the numbers say
| (in billions of US dollars) | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.5B | $0.5B | $0.6B | $0.6B | $0.6B |
| Net income (loss) | ($0.1B) | ($0.2B) | ($0.3B) | ($0.2B) | ($0.0B) |
| Operating cash flow | ($0.0B) | ($0.0B) | ($0.0B) | $0.0B | $0.1B |
While revenue has generally increased over the past five years, 10x Genomics has consistently reported a net loss. However, that loss shrank considerably in 2025. After several years of using cash in its operations, the company's operating cash flow turned positive in 2024 and grew in 2025. The number of shares outstanding has increased from 110 million to 125 million over the last five years, which dilutes the ownership stake of existing shareholders.
What changed in the fine print
In its most recent annual report, management added new warnings about potential lawsuits related to intellectual property. It also added a standard disclaimer that past results are not an indication of future performance. At the same time, the company removed previous warnings about its reliance on government research funding from agencies like the National Institutes of Health (NIH).
What this doesn't tell you
- Why the insiders sold their shares. Sales can be for personal financial planning, diversification, or other reasons not related to the company's future prospects.
- How many shares they sold, or what percentage of their total holdings these sales represent.
- Whether the company will become profitable or if its recent positive operating cash flow will continue.
- The specifics of the intellectual property risks the company now warns about.
Across 688 filings since 2019-05-09, this company has never withdrawn a financial statement, changed auditor, or filed a report late.
Sources
- 2025 annual report0001628280-26-007822
- 2024 annual report0001770787-25-000013
- 2023 annual report0001770787-24-000017
- 2022 annual report0001770787-23-000012
- 2021 annual report0001770787-22-000015
From public SEC filings. Informational only, not investment advice. Do your own due diligence.